A Study of IBI362 in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 731 participants.

Also called NCT05606913

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 731 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05606913
Other papers using this trial's data
  • Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature, 2026-04 DOI, PubMed 41407860

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05606913. Randomized; double masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2024-01-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of IBI362 in Participants With Type 2 Diabetes
Intervention (Drug)
dulaglutide
Intervention (Drug)
IBI362
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05606913
Content hash
4b4c0f53c943300b402f7ec1f2d708d66df1f8e04694ac57f6f8696c1b7d661b